GILD
Gilead Sciences, Inc.$128.99+1.26 (+0.99%)Prev Close$127.75·MCap$168.65B·P/E18.88·Vol2.09M·Yield0.02%
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
31
$62.03M
◆
Net Activity
Net Seller
$62.03M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Gilead Sciences, Inc. (GILD) has been exclusively selling, with 0 insider purchases totaling $0.00 and 31 insider sales totaling $62.03M. The most recent insider transaction was by Dickinson Andrew D (officer: Chief Financial Officer), who sold $422.9K worth of shares on Apr 16, 2026. Gilead Sciences, Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry, with a market cap of $168.65B.
GILD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $140.96 | $422.9K | 176,191 |
| Apr 16, 2026 | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 3,000 | $140.96 | $422.9K | 128,779 |
| Mar 30, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $136.82 | $1.37M | 642,567 |
| Mar 17, 2026 | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $144.23 | $432.7K | 179,191 |
| Mar 17, 2026 | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 3,000 | $144.23 | $432.7K | 131,779 |
| Mar 2, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $144.79 | $1.45M | 648,827 |
| Feb 18, 2026 | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 27,800 | $154.43 | $4.29M | 129,883 |
| Feb 17, 2026 | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $154.43 | $463.3K | 0 |
| Feb 17, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 28,000 | $154.44 | $4.32M | 0 |
| Feb 6, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $150.00 | $17.35M | 613,912 |
| Jan 29, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 20,000 | $139.89 | $2.80M | 561,666 |
| Jan 26, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $135.00 | $15.61M | 566,698 |
| Jan 21, 2026 | Bluestone Jeffrey | Director | Sell | 5,000 | $123.50 | $617.5K | 0 |
| Jan 16, 2026 | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $124.31 | $372.9K | 0 |
| Jan 16, 2026 | Mercier Johanna | officer: Chief Commercial Officer | Sell | 3,000 | $124.31 | $372.9K | 103,221 |
| Jan 5, 2026 | Berger Dietmar | Chief Medical Officer | Sell | 6,944 | $121.60 | $844.4K | 0 |
| Dec 11, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 4,931 | $121.34 | $598.3K | 0 |
| Dec 1, 2025 | Bluestone Jeffrey | Director | Sell | 5,000 | $125.08 | $625.4K | 0 |
| Dec 1, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $126.54 | $1.27M | 0 |
| Nov 18, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 28,000 | $125.86 | $3.52M | 0 |
| Oct 27, 2025 | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 241 | $120.94 | $29.1K | 0 |
| Oct 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.08 | $295.2K | 0 |
| Sep 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $113.57 | $283.9K | 0 |
| Sep 11, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 1,819 | $115.25 | $209.6K | 0 |
| Sep 11, 2025 | Wilfong Diane E. | Interim Corp Controller & CAO | Sell | 338 | $115.25 | $39.0K | 0 |
| Aug 29, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $113.63 | $1.14M | 0 |
| Aug 18, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.53 | $296.3K | 0 |
| Jul 28, 2025 | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 3,823 | $116.20 | $444.2K | 0 |
| Jul 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $111.03 | $277.6K | 0 |
| Jul 1, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $110.45 | $1.10M | 0 |
| Jun 17, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 3,000 | $110.17 | $330.5K | 0 |
| Mar 12, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 3,907 | $117.21 | $457.9K | 0 |
| Feb 19, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $104.09 | $260.2K | 0 |
| Feb 6, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 108,156 | $97.99 | $10.60M | 0 |
| Feb 3, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 142,180 | $97.22 | $13.82M | 129,873-52% |
| Jan 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $91.35 | $228.4K | 129,873 |
| Dec 23, 2024 | GILEAD SCIENCES, INC. | 10% Owner | Buy | 940,499 | $21.37 | $20.10M | 2,209,471+74% |
| Dec 19, 2024 | GILEAD SCIENCES, INC. | 10% Owner | Buy | 1,759,978 | $1.04 | $1.83M | 9,105,451 |
| Dec 17, 2024 | Dickinson Andrew D | Chief Financial Officer | Sell | 8,500 | $91.96 | $781.7K | 132,373 |
| Dec 3, 2024 | Dickinson Andrew D | Chief Financial Officer | Sell | 248,645 | $92.76 | $23.07M | 266,849-48% |
| Nov 29, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 164,211 | $91.92 | $15.09M | 187,718-47% |
| Nov 27, 2024 | Bluestone Jeffrey | Director | Sell | 6,788 | $91.39 | $620.4K | 8,920-43% |
| Nov 7, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 5,000 | $91.28 | $456.4K | 73,127 |
| Nov 7, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 25,590 | $91.50 | $2.34M | 104,599 |
| Oct 2, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $83.83 | $167.7K | 100,189 |
| Sep 13, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 29,357 | $83.78 | $2.46M | 91,559 |
| Sep 13, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 21,246 | $84.50 | $1.80M | 102,189 |
| Aug 29, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 9,513 | $78.03 | $742.3K | 105,466 |
| Aug 14, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 5,490 | $73.98 | $406.1K | 114,979 |
| Jul 1, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $68.63 | $137.3K | 96,380 |
Showing 1–50 of 75
1 / 2
GILD Insider Buying Activity
The following table shows recent insider purchases of Gilead Sciences, Inc. (GILD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 23, 2024 | GILEAD SCIENCES, INC. | 10% Owner | Buy | 940,499 | $21.37 | $20.10M | 2,209,471+74% |
| Dec 19, 2024 | GILEAD SCIENCES, INC. | 10% Owner | Buy | 1,759,978 | $1.04 | $1.83M | 9,105,451 |
GILD Insider Selling Activity
The following table shows recent insider sales of Gilead Sciences, Inc. (GILD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $140.96 | $422.9K | 176,191 |
| Apr 16, 2026 | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 3,000 | $140.96 | $422.9K | 128,779 |
| Mar 30, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $136.82 | $1.37M | 642,567 |
| Mar 17, 2026 | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $144.23 | $432.7K | 179,191 |
| Mar 17, 2026 | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 3,000 | $144.23 | $432.7K | 131,779 |
| Mar 2, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $144.79 | $1.45M | 648,827 |
| Feb 18, 2026 | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 27,800 | $154.43 | $4.29M | 129,883 |
| Feb 17, 2026 | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $154.43 | $463.3K | 0 |
| Feb 17, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 28,000 | $154.44 | $4.32M | 0 |
| Feb 6, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $150.00 | $17.35M | 613,912 |
| Jan 29, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 20,000 | $139.89 | $2.80M | 561,666 |
| Jan 26, 2026 | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $135.00 | $15.61M | 566,698 |
| Jan 21, 2026 | Bluestone Jeffrey | Director | Sell | 5,000 | $123.50 | $617.5K | 0 |
| Jan 16, 2026 | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $124.31 | $372.9K | 0 |
| Jan 16, 2026 | Mercier Johanna | officer: Chief Commercial Officer | Sell | 3,000 | $124.31 | $372.9K | 103,221 |
| Jan 5, 2026 | Berger Dietmar | Chief Medical Officer | Sell | 6,944 | $121.60 | $844.4K | 0 |
| Dec 11, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 4,931 | $121.34 | $598.3K | 0 |
| Dec 1, 2025 | Bluestone Jeffrey | Director | Sell | 5,000 | $125.08 | $625.4K | 0 |
| Dec 1, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $126.54 | $1.27M | 0 |
| Nov 18, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 28,000 | $125.86 | $3.52M | 0 |
| Oct 27, 2025 | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 241 | $120.94 | $29.1K | 0 |
| Oct 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.08 | $295.2K | 0 |
| Sep 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $113.57 | $283.9K | 0 |
| Sep 11, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 1,819 | $115.25 | $209.6K | 0 |
| Sep 11, 2025 | Wilfong Diane E. | Interim Corp Controller & CAO | Sell | 338 | $115.25 | $39.0K | 0 |
| Aug 29, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $113.63 | $1.14M | 0 |
| Aug 18, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.53 | $296.3K | 0 |
| Jul 28, 2025 | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 3,823 | $116.20 | $444.2K | 0 |
| Jul 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $111.03 | $277.6K | 0 |
| Jul 1, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $110.45 | $1.10M | 0 |
| Jun 17, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 3,000 | $110.17 | $330.5K | 0 |
| Mar 12, 2025 | Mercier Johanna | Chief Commercial Officer | Sell | 3,907 | $117.21 | $457.9K | 0 |
| Feb 19, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $104.09 | $260.2K | 0 |
| Feb 6, 2025 | O'Day Daniel Patrick | Chairman & CEO | Sell | 108,156 | $97.99 | $10.60M | 0 |
| Feb 3, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 142,180 | $97.22 | $13.82M | 129,873-52% |
| Jan 16, 2025 | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $91.35 | $228.4K | 129,873 |
| Dec 17, 2024 | Dickinson Andrew D | Chief Financial Officer | Sell | 8,500 | $91.96 | $781.7K | 132,373 |
| Dec 3, 2024 | Dickinson Andrew D | Chief Financial Officer | Sell | 248,645 | $92.76 | $23.07M | 266,849-48% |
| Nov 29, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 164,211 | $91.92 | $15.09M | 187,718-47% |
| Nov 27, 2024 | Bluestone Jeffrey | Director | Sell | 6,788 | $91.39 | $620.4K | 8,920-43% |
| Nov 7, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 5,000 | $91.28 | $456.4K | 73,127 |
| Nov 7, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 25,590 | $91.50 | $2.34M | 104,599 |
| Oct 2, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $83.83 | $167.7K | 100,189 |
| Sep 13, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 29,357 | $83.78 | $2.46M | 91,559 |
| Sep 13, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 21,246 | $84.50 | $1.80M | 102,189 |
| Aug 29, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 9,513 | $78.03 | $742.3K | 105,466 |
| Aug 14, 2024 | Mercier Johanna | Chief Commercial Officer | Sell | 5,490 | $73.98 | $406.1K | 114,979 |
| Jul 1, 2024 | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $68.63 | $137.3K | 96,380 |
GILD Insiders
Similar Stocks to GILD
LLY
Eli Lilly and Company
$865.58-0.35%
$869.14B
JNJ
Johnson & Johnson
$226.84+0.65%
$555.94B
ABBV
AbbVie Inc.
$197.07-0.13%
$360.31B
MRK
Merck & Co., Inc.
$110.37+0.13%
$289.58B
AMGN
Amgen Inc.
$338.27-0.58%
$188.76B
PFE
Pfizer Inc.
$26.52-1.03%
$156.54B
BMY
Bristol-Myers Squibb Company
$58.09+0.53%
$120.73B
BIIB
Biogen Inc.
$183.22+1.33%
$26.91B